A Phase 1 interventional study of Pitavastatin in Metabolic Syndrome, sponsored by Kowa Research Europe. Completed at 1 site in United Kingdom. Open to male participants aged 30 Years to 65 Years. Per ClinicalTrials.gov, last updated 2013-07-22.
Sponsored by Kowa Research Europe (part of Kowa Company, Ltd.) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies in Metabolic Syndrome with a site in United Kingdom — 9 open to participants now, 10 under way, none of them phase 3. Metabolic Syndrome · United Kingdom.
Among the 55 studies in Metabolic Syndrome with a site in United Kingdom, this one is the 41st largest by enrollment of the 48 interventional ones that give a count, is the only one that started in 2010, is the only one in phase 1, and was the 10th registered.
2,117 studies on the registry are indexed under Metabolic Syndrome; 347 are open to participants now.
Browse Metabolic Syndrome studies →9 of the 55 studies in Metabolic Syndrome with a site in United Kingdom are open now. Recruiting first, the newest first:
University of Liverpool · Sites in United Kingdom
Ages 40+ · Healthy volunteers
University of Nottingham · Sites in United Kingdom
Ages 50–65 · Healthy volunteers
University of Central Lancashire · Sites in United Kingdom
Ages 18–65 · Healthy volunteers
Eclat Srl. · Sites in United Kingdom
Ages 23+
Salah Snouda · Sites in United Kingdom
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 232 Metabolic Syndrome studies recruiting now, 68 (29%) set no upper age limit and 135 (58%) stop at 75 or younger; 20 take children under 18; 80 take healthy volunteers.
This study: 30 Years to 65 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
55 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 3 · Phase 4 2
First in 2005; this study’s year is marked. 1 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 14 is below the median of 60 across 1,573 interventional studies indexed under Metabolic Syndrome.
Median enrollment 45 across the 48 interventional studies, 100 across the 7 observational. Of the 40 that completed or were terminated, 4 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 55 have an industry lead sponsor. The 10 most frequent:
This study is registered under Kowa Research Europe, one of the names counted as Kowa Company, Ltd.. Under that name alone:
Kowa Research Europe is the lead sponsor of 10 studies on the registry; none are open to participants now.
Kowa Company, Ltd. has 1 study filed under Metabolic Syndrome — fewer than ten, so there is no comparison to draw.
5 of the studies in Metabolic Syndrome with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07606872Salah SnoudaValidation of the Snouda Metabolic Score for Phenotyping and Guiding Reversal in Type 2 Diabetes | 2026-12 |
| NCT06795438University of Central LancashireEffects of Green Tea on Cardiometabolic Outcomes | 2027-02-01 |
| NCT07474233Liverpool John Moores UniversityAssociations Between Dietary Patterns, LDL Aggregation, and Cardiometabolic Health | 2027-05 |
| NCT07462871Liverpool John Moores UniversityComparative Effects of Carnivore and Mediterranean-style Diets on LDL Aggregation and Cardiometabolic Health | 2027-06 |
| NCT06784154University of LiverpoolThe Role of Ectopic Fat and Heart Attack Risk in HIV | 2027-06-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 55 studies in Metabolic Syndrome with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to examine in detail the acute and chronic effects of pitavastatin on plasma lipid transport and atheroma biomarkers in patients at elevated risk for the premature development of atherosclerosis (CAPITAIN).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
4 mg tablets of pitavastatin by oral route for a period of 6 months
Drug: Pitavastatin
Change from baseline to Day 180 in plasma biomarkers of inflammation and atherosclerosis, including monocytes, lymphocytes, endothelial adhesion proteins, atherogenic lipoproteins and cardioprotective HDL
Time frame: 180 days
The record gives a start of Oct 2010, a primary completion of Jun 2012 and a completion of Jun 2012. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pitavastatin